CN109789200A - 用改善的配制剂使黄病毒稳定化的组合物和方法 - Google Patents

用改善的配制剂使黄病毒稳定化的组合物和方法 Download PDF

Info

Publication number
CN109789200A
CN109789200A CN201780047777.5A CN201780047777A CN109789200A CN 109789200 A CN109789200 A CN 109789200A CN 201780047777 A CN201780047777 A CN 201780047777A CN 109789200 A CN109789200 A CN 109789200A
Authority
CN
China
Prior art keywords
flavivirus
composition
concentration
virus
preparaton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780047777.5A
Other languages
English (en)
Chinese (zh)
Inventor
J.A.莱文古德
L.M.斯特兰吉
S.M.厄尔布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of CN109789200A publication Critical patent/CN109789200A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CN201780047777.5A 2016-08-03 2017-08-03 用改善的配制剂使黄病毒稳定化的组合物和方法 Pending CN109789200A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370611P 2016-08-03 2016-08-03
US62/370,611 2016-08-03
PCT/US2017/045375 WO2018027075A1 (en) 2016-08-03 2017-08-03 Compositions and methods for stabilizing flaviviruses with improved formulations

Publications (1)

Publication Number Publication Date
CN109789200A true CN109789200A (zh) 2019-05-21

Family

ID=59593235

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780047777.5A Pending CN109789200A (zh) 2016-08-03 2017-08-03 用改善的配制剂使黄病毒稳定化的组合物和方法

Country Status (13)

Country Link
US (3) US10835597B2 (enExample)
EP (1) EP3493839A1 (enExample)
JP (2) JP7280179B2 (enExample)
KR (2) KR102576789B1 (enExample)
CN (1) CN109789200A (enExample)
AU (2) AU2017305498B2 (enExample)
CA (1) CA3030343A1 (enExample)
CO (1) CO2019001448A2 (enExample)
MX (2) MX2019001473A (enExample)
PH (1) PH12019500003A1 (enExample)
SG (2) SG10201913040SA (enExample)
TW (2) TWI766876B (enExample)
WO (1) WO2018027075A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588859A (zh) * 2020-06-02 2020-08-28 成都可恩生物科技有限公司 一种冻干保护剂及其应用和冻干苗及其制备方法
CN112501024A (zh) * 2020-12-03 2021-03-16 英科新创（苏州）生物科技有限公司 一种体外诊断试剂盒通用型质控品保存液
WO2021168764A1 (zh) * 2020-02-28 2021-09-02 台湾粒线体应用技术股份有限公司 冷冻保存剂与使用其的线粒体冷冻保存方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
BR112019011900A2 (pt) * 2016-12-23 2019-11-26 Serum Institute Of India Private Limited métodos melhorados para aumentar a produtividade de anticorpos na cultura de células de mamíferos e minimizar a agregação durante os processos downs-tream, processos de formulação, e formulações de anticorpos estáveis obtidas dos mesmos
IL316312A (en) 2017-12-07 2024-12-01 Merck Sharp ַ& Dohme Llc Dengue virus vaccine compound formulations
ES2941526T3 (es) 2018-03-20 2023-05-23 Nat Res Council Canada Un método para liofilizar cepas vacunales vivas de Francisella tularensis
KR102649069B1 (ko) 2018-05-31 2024-03-19 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물
CN112261871B (zh) 2018-07-28 2022-05-17 韩国外泌体生技有限公司 用于使外排体冻干的方法
KR102163806B1 (ko) 2018-07-30 2020-10-07 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
EP3890505A4 (en) * 2018-12-05 2022-11-02 Seres Therapeutics, Inc. COMPOSITIONS FOR STABILIZING BACTERIA AND THEIR USES
WO2021034349A1 (en) 2019-08-16 2021-02-25 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis a
US20240076631A2 (en) * 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
CN113549653B (zh) * 2020-04-23 2024-03-22 上海赛比曼生物科技有限公司 用于慢病毒载体长期存贮的组合试剂
EP4012025A1 (en) * 2020-12-10 2022-06-15 Univerzita Palackého v Olomouci Transport medium for samples containing nucleic acids and/or proteins
CN113730592B (zh) * 2021-09-03 2023-12-19 吉林正业生物制品股份有限公司 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用
WO2023158989A1 (en) * 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
AU2023365824B2 (en) * 2022-10-18 2026-06-04 Takeda Vaccines, Inc. Dengue vaccine formulation
WO2025027616A1 (en) * 2023-08-01 2025-02-06 Serum Institute Of India Private Limited Freeze-dried viral vaccine compositions and method of manufacturing thereof
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122946A1 (en) * 2023-12-07 2025-06-12 Rovin Richard A Zika viruses and uses thereof
WO2026141382A1 (ja) * 2024-12-24 2026-07-02 Ｋｍバイオロジクス株式会社 弱毒生４価デングウイルスを含む組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
CN101679954A (zh) * 2007-04-06 2010-03-24 伊维拉根公司 用于活的减毒病毒的方法和组合物
CN102089002A (zh) * 2008-07-09 2011-06-08 赛诺菲巴斯德有限公司 稳定剂和含一种或多种减毒活黄病毒的疫苗组合物
CN104984357A (zh) * 2015-06-02 2015-10-21 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
CN109069615A (zh) * 2016-04-13 2018-12-21 武田疫苗股份有限公司 在儿童和年轻人中针对登革热病毒接种疫苗的组合物和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101808657A (zh) 2006-11-07 2010-08-18 赛诺菲巴斯德生物制剂公司 冻干法稳定疫苗

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
CN101679954A (zh) * 2007-04-06 2010-03-24 伊维拉根公司 用于活的减毒病毒的方法和组合物
CN102089002A (zh) * 2008-07-09 2011-06-08 赛诺菲巴斯德有限公司 稳定剂和含一种或多种减毒活黄病毒的疫苗组合物
CN104984357A (zh) * 2015-06-02 2015-10-21 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
CN109069615A (zh) * 2016-04-13 2018-12-21 武田疫苗股份有限公司 在儿童和年轻人中针对登革热病毒接种疫苗的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O’NEIL WIGGAN等: "Novel formulations enhance the thermal stability of live attenuated flavivirus vaccines", 《VACCINE》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168764A1 (zh) * 2020-02-28 2021-09-02 台湾粒线体应用技术股份有限公司 冷冻保存剂与使用其的线粒体冷冻保存方法
CN115023135A (zh) * 2020-02-28 2022-09-06 台湾粒线体应用技术股份有限公司 冷冻保存剂与使用其的线粒体冷冻保存方法
CN115023135B (zh) * 2020-02-28 2024-04-19 台湾粒线体应用技术股份有限公司 线粒体的冷冻保存剂与使用其的线粒体冷冻保存方法
US12429406B2 (en) 2020-02-28 2025-09-30 Taiwan Mitochondrion Applied Technology Co., Ltd. Agent for cryopreservation and method for cryopreservation of mitochondria using the same
CN111588859A (zh) * 2020-06-02 2020-08-28 成都可恩生物科技有限公司 一种冻干保护剂及其应用和冻干苗及其制备方法
CN111588859B (zh) * 2020-06-02 2021-09-03 成都可恩生物科技有限公司 一种冻干保护剂及其应用和冻干苗及其制备方法
CN112501024A (zh) * 2020-12-03 2021-03-16 英科新创（苏州）生物科技有限公司 一种体外诊断试剂盒通用型质控品保存液

Also Published As

Publication number Publication date
US10835597B2 (en) 2020-11-17
TW201807191A (zh) 2018-03-01
US20230263880A1 (en) 2023-08-24
KR102576789B1 (ko) 2023-09-12
KR20230132887A (ko) 2023-09-18
WO2018027075A1 (en) 2018-02-08
AU2023203715A1 (en) 2023-07-06
US20210121558A1 (en) 2021-04-29
TWI766876B (zh) 2022-06-11
SG11201811831SA (en) 2019-01-30
BR112019001299A2 (pt) 2019-04-30
SG10201913040SA (en) 2020-03-30
JP2019524771A (ja) 2019-09-05
US20190184004A1 (en) 2019-06-20
CA3030343A1 (en) 2018-02-08
MX2022010907A (es) 2022-10-07
MX2019001473A (es) 2019-09-23
JP7280179B2 (ja) 2023-05-23
TW202309276A (zh) 2023-03-01
AU2017305498B2 (en) 2023-03-30
AU2017305498A1 (en) 2019-01-24
CO2019001448A2 (es) 2019-04-30
EP3493839A1 (en) 2019-06-12
JP2023052624A (ja) 2023-04-11
KR20190034598A (ko) 2019-04-02
PH12019500003A1 (en) 2019-10-14
US11701421B2 (en) 2023-07-18

Similar Documents

Publication Publication Date Title
US11701421B2 (en) Compositions and methods for stabilizing flaviviruses with improved formulations
ES2636680T3 (es) Preparación liofilizada de toxina botulínica
BRPI0813948B1 (pt) Composição líquida farmacêutica de toxina botulínica com estabilidade melhorada
US10806781B2 (en) Compositions and methods for live, attenuated alphavirus formulations
US20200306361A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
JP2025000889A (ja) 液体組成物中の生モリクテス綱細菌の安定化
Dubrovina et al. Composition of the stabilizer and conditions of lyophilization for preserving infectious activity of influenza virus
TWI527598B (zh) 將致免疫組成物維持可供投與動物的方法
HK1220358B (en) Compositions and methods for live, attenuated alphavirus formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination